Abstract
Recurrence of Crohns disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients ’ management and, ultimately, highlight the molecular mechanisms at the very basis of Crohns disease.
Current Drug Targets
Title: Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows
Volume: 11 Issue: 2
Author(s): D. Sorrentino, A. Paviotti and G. Fiorino
Affiliation:
Abstract: Recurrence of Crohns disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immuno-soppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients ’ management and, ultimately, highlight the molecular mechanisms at the very basis of Crohns disease.
Export Options
About this article
Cite this article as:
Sorrentino D., Paviotti A. and Fiorino G., Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309920
DOI https://dx.doi.org/10.2174/138945010790309920 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intraperitoneal Drug Therapy: An Advantage
Current Clinical Pharmacology Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Intracellular Disposition of Methotrexate in Acute Lymphoblastic Leukemia in Children
Current Drug Metabolism Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms
Current Cancer Drug Targets Chemical Intuition in Drug Design and Discovery
Current Topics in Medicinal Chemistry Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design N-glycomic Analysis of Z(IgA1) Partitioned Serum and Salivary Immunoglobulin A by Capillary Electrophoresis
Current Molecular Medicine Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Cancer Therapy Based on a Mechanism of Action for Controlling the Immune System and the Resulting Patent Portfolio
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Detection of Clonal Immunoglobulin and T-Cell Receptor Gene Recombination in Hematological Malignancies: Monitoring Minimal Residual Disease
Cardiovascular & Hematological Disorders-Drug Targets Laboratory Monitoring of Hematological and Hepatic Parameters in Ambulatory Patients Receiving Alpha-Methyldopa in a Nigerian Tertiary Care Setting
Current Drug Safety The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & DC Action Under Immunosuppressive Conditions?
Current Medicinal Chemistry Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family Proteins
Current Drug Targets Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry